AR064031A1 - Compuestos de azaindolilo y metodos de uso - Google Patents
Compuestos de azaindolilo y metodos de usoInfo
- Publication number
- AR064031A1 AR064031A1 ARP070105307A ARP070105307A AR064031A1 AR 064031 A1 AR064031 A1 AR 064031A1 AR P070105307 A ARP070105307 A AR P070105307A AR P070105307 A ARP070105307 A AR P070105307A AR 064031 A1 AR064031 A1 AR 064031A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr19r20
- nhc
- cr14r15
- noc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 147
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 8
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 8
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000002547 anomalous effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86805506P | 2006-11-30 | 2006-11-30 | |
| US91762007P | 2007-05-11 | 2007-05-11 | |
| US94474307P | 2007-06-18 | 2007-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064031A1 true AR064031A1 (es) | 2009-03-04 |
Family
ID=39169665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105307A AR064031A1 (es) | 2006-11-30 | 2007-11-29 | Compuestos de azaindolilo y metodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7855216B2 (enExample) |
| EP (1) | EP2099796B1 (enExample) |
| JP (1) | JP5211063B2 (enExample) |
| AR (1) | AR064031A1 (enExample) |
| AT (1) | ATE511509T1 (enExample) |
| AU (1) | AU2007325123B2 (enExample) |
| CA (1) | CA2672327A1 (enExample) |
| CL (1) | CL2007003444A1 (enExample) |
| DK (1) | DK2099796T3 (enExample) |
| PE (1) | PE20081354A1 (enExample) |
| PL (1) | PL2099796T3 (enExample) |
| PT (1) | PT2099796E (enExample) |
| TW (1) | TW200829586A (enExample) |
| WO (1) | WO2008067481A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526267A (ja) * | 2008-07-03 | 2011-10-06 | バイエル ファーマ アクチエンゲゼルシャフト | 化合物および放射性医薬品の製造方法 |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| BR112012022801B8 (pt) | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| SG10201505951VA (en) * | 2010-07-30 | 2015-08-28 | Oncotherapy Science Inc | Quinoline derivatives and melk inhibitors containing the same |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| KR102642411B1 (ko) * | 2017-05-19 | 2024-02-28 | 엔플렉션 테라퓨틱스, 인코포레이티드 | 피부병 치료를 위한 피롤로피리딘-아닐린 화합물 |
| ES2913213T3 (es) | 2017-05-19 | 2022-06-01 | Nflection Therapeutics Inc | Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos |
| US11859252B2 (en) | 2017-09-08 | 2024-01-02 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| JP7393808B2 (ja) | 2018-11-20 | 2023-12-07 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのナフチリジノン－アニリン化合物 |
| CN117551073A (zh) | 2018-11-20 | 2024-02-13 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病噻吩基苯胺化合物 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN118591373A (zh) | 2021-11-23 | 2024-09-03 | 恩福莱克逊治疗有限公司 | 吡咯并吡啶-苯胺化合物的制剂 |
| JP2025502943A (ja) * | 2022-01-28 | 2025-01-30 | インシリコ メディシン アイピー リミテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ１（ｅｎｐｐ１）阻害剤およびその使用 |
| CN119013276A (zh) * | 2022-03-04 | 2024-11-22 | 三进制药株式会社 | 新型杂环化合物和包含该化合物的药物组合物 |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2025026383A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| KR20250067072A (ko) * | 2023-11-07 | 2025-05-14 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| AU2003239150A1 (en) | 2002-04-23 | 2003-11-10 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo |
| US6929411B2 (en) * | 2003-09-03 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Selectable control of raster image processor |
| GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| DE102005013621A1 (de) * | 2005-03-24 | 2006-09-28 | Curacyte Discovery Gmbh | Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika |
| AR070127A1 (es) * | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
-
2007
- 2007-11-29 PE PE2007001679A patent/PE20081354A1/es not_active Application Discontinuation
- 2007-11-29 WO PCT/US2007/085962 patent/WO2008067481A1/en not_active Ceased
- 2007-11-29 EP EP07854844A patent/EP2099796B1/en active Active
- 2007-11-29 US US11/947,656 patent/US7855216B2/en not_active Expired - Fee Related
- 2007-11-29 JP JP2009539490A patent/JP5211063B2/ja not_active Expired - Fee Related
- 2007-11-29 DK DK07854844.3T patent/DK2099796T3/da active
- 2007-11-29 PL PL07854844T patent/PL2099796T3/pl unknown
- 2007-11-29 CA CA002672327A patent/CA2672327A1/en not_active Abandoned
- 2007-11-29 CL CL200703444A patent/CL2007003444A1/es unknown
- 2007-11-29 AU AU2007325123A patent/AU2007325123B2/en not_active Ceased
- 2007-11-29 AT AT07854844T patent/ATE511509T1/de active
- 2007-11-29 PT PT07854844T patent/PT2099796E/pt unknown
- 2007-11-29 AR ARP070105307A patent/AR064031A1/es unknown
- 2007-11-29 TW TW096145474A patent/TW200829586A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007325123A1 (en) | 2008-06-05 |
| US7855216B2 (en) | 2010-12-21 |
| WO2008067481A1 (en) | 2008-06-05 |
| ATE511509T1 (de) | 2011-06-15 |
| EP2099796A1 (en) | 2009-09-16 |
| EP2099796B1 (en) | 2011-06-01 |
| JP5211063B2 (ja) | 2013-06-12 |
| PL2099796T3 (pl) | 2011-10-31 |
| HK1135099A1 (en) | 2010-05-28 |
| TW200829586A (en) | 2008-07-16 |
| PT2099796E (pt) | 2011-09-06 |
| CA2672327A1 (en) | 2008-06-05 |
| AU2007325123B2 (en) | 2012-12-13 |
| PE20081354A1 (es) | 2008-11-14 |
| CL2007003444A1 (es) | 2008-06-27 |
| DK2099796T3 (da) | 2011-09-05 |
| JP2010511626A (ja) | 2010-04-15 |
| US20080242655A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064031A1 (es) | Compuestos de azaindolilo y metodos de uso | |
| AR062468A1 (es) | Compuestos de azabenzofuranil y metodos de uso | |
| AR062469A1 (es) | Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos. | |
| AR069803A1 (es) | 5- anilinoimiazopiridinas y metodos de uso | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| RU2011103434A (ru) | Изоиндолоны и способы их применения | |
| AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
| CY1124357T1 (el) | Προσδιορισμος ανισορροπιας αλληλουχιας νουκλεϊκων οξεων | |
| AR058542A1 (es) | Compuestos herbicidas derivados de isoxazolina, procesos de preparacon, composiciones que los comprenden y uso en el control o inhibicion de plantas. | |
| PE20071022A1 (es) | Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept) | |
| AR050793A1 (es) | Derivados de isoxazolina, procedimientos para su preparacion y su uso como herbicidas | |
| BR112018016671A2 (pt) | sulfonilureias e compostos relacionados e uso do mesmo | |
| PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| AR054814A1 (es) | Derivados de piridazina | |
| PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
| PE20070768A1 (es) | Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion | |
| PE20130008A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| CY1115302T1 (el) | Ενωση οξαζολιου και φαρμακευτικη συνθεση | |
| PE20130647A1 (es) | Indoles | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| CO6220878A2 (es) | Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo | |
| CO6220907A2 (es) | 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas | |
| PE20120659A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |